Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15596306 | 0.84 | GPR119 (0.67) | USP30GPR119PDE10A | |
| SCHEMBL10111733 | 0.84 | GPR119 (0.67) | USP30GPR119PDE10A | |
| SCHEMBL6324400 | 0.82 | CHRNB2 (0.53) | HPGDSUSP30GPR119CKS1BSKP1 | |
| SCHEMBL652572 | 0.82 | PDE10A (0.54) | USP30GPR119CKS1BSKP1SKP2 | |
| SCHEMBL652571 | 0.82 | PDE10A (0.54) | USP30GPR119CKS1BSKP1SKP2 | |
| SCHEMBL929933 | 0.82 | NR1H2 (0.45) | USP30GPR119PDE10A | |
| SCHEMBL6324537 | 0.81 | PDE10A (0.52) | HPGDSUSP30GPR119CKS1BSKP1 | |
| SCHEMBL928414 | 0.80 | NPC1 (0.54) | USP30GPR119PDE10A | |
| SCHEMBL930418 | 0.80 | USP30 (0.54) | HPGDSUSP30GPR119CKS1BSKP1 | |
| SCHEMBL929692 | 0.79 | GPR119 (0.50) | GPR119PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | HPGDS 3755/4885USP30 4503/4885GPR119 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.